|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/01/21 Celldex Therapeutics, Inc. 8-K:5,9 7/01/21 11:770K Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 24K 2: EX-10.1 Material Contract HTML 57K 11: EX-10.10 Material Contract HTML 56K 3: EX-10.2 Material Contract HTML 57K 4: EX-10.3 Material Contract HTML 56K 5: EX-10.4 Material Contract HTML 57K 6: EX-10.5 Material Contract HTML 57K 7: EX-10.6 Material Contract HTML 58K 8: EX-10.7 Material Contract HTML 58K 9: EX-10.8 Material Contract HTML 57K 10: EX-10.9 Material Contract HTML 56K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 1, 2021
CELLDEX THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 000-15006 | 13-3191702 | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
Perryville III Building, 53 Frontage Road, Suite 220,
(Address of principal executive offices) (Zip Code)
(908) 200-7500
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $.001 | CLDX | Nasdaq Capital Market |
C:
Item 5.02(e). Compensatory Arrangements of Certain Officers.
Celldex Therapeutics, Inc. (the “Company”) entered into amended and restated employment agreements with each of its executive officers: Anthony S. Marucci, President and Chief Executive Officer; Sam Martin, Senior Vice President, Chief Financial Officer and Secretary; Tibor Keler, Ph.D., Executive Vice President and Chief Scientific Officer; Ronald A. Pepin, Ph.D., Senior Vice President and Chief Business Officer; Sarah Cavanaugh, Senior Vice President of Corporate Affairs and Administration; Margo Heath-Chiozzi, M.D., Senior Vice President of Regulatory Affairs; Elizabeth Crowley, Senior Vice President and Chief Product Development Officer; Richard Wright, Ph.D., Senior Vice President and Chief Commercial Officer; Diane Young, M.D., Senior Vice President, Chief Medical Officer; and Freddy Jimenez, Esq., Senior Vice President and General Counsel. Each of these employment agreements is effective July 1, 2021.
The executive employment agreements between the Company and its executive officers were amended to reflect the following current salary and bonus targets and to standardize language in the contracts.
| Name | Annual Salary | Bonus Target | ||||||
| Anthony S. Marucci | $ | 680,908 | 60 | % | ||||
| Tibor Keler, Ph.D. | $ | 483,645 | 45 | % | ||||
| Sarah Cavanaugh | $ | 350,000 | 40 | % | ||||
| Elizabeth Crowley | $ | 388,632 | 40 | % | ||||
| Margo Heath-Chiozzi, M.D. | $ | 417,659 | 40 | % | ||||
| Freddy Jimenez | $ | 391,230 | 40 | % | ||||
| Sam Martin | $ | 412,820 | 40 | % | ||||
| Ronald Pepin, Ph.D. | $ | 366,586 | 40 | % | ||||
| Richard Wright, Ph.D. | $ | 377,306 | 40 | % | ||||
| Diane Young, M.D. | $ | 438,141 | 40 | % | ||||
The employment agreements have an initial term through December 31, 2021 and shall automatically renew for additional one year terms unless either party gives ninety (90) days prior written notice of its intent not to renew. The Company may terminate the employment agreements without cause, on 90-days’ prior notice, or for cause, subject to a 30-day cure period in certain circumstances. The executive may terminate the employment agreement for good reason (as defined in the executive employment agreement) on 30-days’ prior notice.
The foregoing description of the employment agreements with each of the Company’s executive officers is intended to be a summary and is qualified in its entirety by reference to such documents, which are attached as Exhibits 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9 and 10.10 and which are incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
C:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CELLDEX THERAPEUTICS, INC. | ||
| Dated: July 1, 2021 | By: | /s/ Sam Martin |
| Name: | Sam Martin | |
| Title: | Senior Vice President and Chief Financial Officer | |
C:
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 12/31/21 | 10-K | |||
| Filed on / For Period end: | 7/1/21 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/26/24 Celldex Therapeutics, Inc. 10-K 12/31/23 87:8.5M Toppan Merrill/FA2 2/28/23 Celldex Therapeutics, Inc. 10-K 12/31/22 85:8.1M Toppan Merrill/FA 2/28/22 Celldex Therapeutics, Inc. 10-K 12/31/21 86:8M Toppan Merrill/FA 8/05/21 Celldex Therapeutics, Inc. 10-Q 6/30/21 58:5.5M Toppan Merrill/FA 7/15/21 Celldex Therapeutics, Inc. 424B5 7/14/21 1:696K Toppan Merrill/FA 7/12/21 Celldex Therapeutics, Inc. 424B5 1:687K Toppan Merrill/FA |